08:04 AM EDT, 07/07/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Monday that the European Medicines Agency has granted orphan drug designation to bexobrutideg, a treatment for Waldenstrom macroglobulinemia, or WM, a rare type of blood cancer.

Bexobrutideg is currently being evaluated in a phase 1 clinical trial in patients with relapsed or refractory B-cell malignancies, including WM.

The EMA grants orphan drug status to therapies intended for the treatment, diagnosis, or prevention of rare diseases that affect fewer than 5 in 10,000 people in the European Union. The designation provides Nurix with 10 years of market exclusivity in the EU upon approval and other incentives.

Bexobrutideg received the US Food and Drug Administration's fast track designation in December 2024 for the treatment of WM.

Nurix shares were more than 5% higher in premarket trading.